See more : Anzheng Fashion Group Co., Ltd. (603839.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Rhythm Pharmaceuticals, Inc. (RYTM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rhythm Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Urbanimmersive Inc. (UBMRF) Income Statement Analysis – Financial Results
- MVV Energie AG (MVV1.DE) Income Statement Analysis – Financial Results
- Visiomed Group (VMGBS.PA) Income Statement Analysis – Financial Results
- Compagnie des Alpes SA (CDA.PA) Income Statement Analysis – Financial Results
- EnSync, Inc. (ESNC) Income Statement Analysis – Financial Results
Rhythm Pharmaceuticals, Inc. (RYTM)
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.43M | 23.64M | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.30M | 2.13M | 599.00K | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 68.13M | 21.51M | 2.56M | -690.00K | -834.00K | -442.00K | -223.00K | -144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 87.99% | 90.98% | 81.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 134.95M | 108.63M | 104.13M | 90.45M | 109.45M | 50.34M | 22.89M | 19.59M | 7.15M | 5.28M | 18.02M | 15.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.53M | 92.03M | 68.49M | 46.13M | 36.55M | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Other Expenses | 0.00 | -790.00K | 100.00M | 0.00 | 0.00 | 0.00 | -1.86M | 0.00 | -500.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 252.48M | 200.66M | 172.61M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Cost & Expenses | 261.79M | 202.80M | 173.21M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Interest Income | 13.95M | 4.03M | 447.00K | 2.58M | 5.27M | 4.35M | 566.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.89M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.76M | 1.40M | 1.16M | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 500.00K | 6.49M | 20.00K | 17.00K |
| EBITDA | -168.46M | -174.52M | -68.45M | -135.89M | -145.17M | -77.98M | -32.19M | -25.76M | -10.07M | 0.00 | -21.41M | -18.12M |
| EBITDA Ratio | -217.58% | -744.22% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -184.36M | -179.16M | -170.06M | -136.58M | -146.00M | -78.42M | -32.41M | -25.91M | -10.57M | -6.49M | -21.45M | -18.14M |
| Operating Income Ratio | -238.10% | -757.92% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 243.00K | -1.96M | 100.45M | 2.58M | 5.27M | 4.35M | -1.30M | 33.00K | -500.00K | 0.00 | 17.00K | 8.00K |
| Income Before Tax | -184.11M | -181.12M | -69.61M | -134.00M | -140.73M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Income Before Tax Ratio | -237.79% | -766.22% | -2,207.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 564.00K | 1.96M | -1.61M | -3.27M | -6.11M | 4.35M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -184.68M | -183.08M | -68.01M | -130.73M | -134.62M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Net Income Ratio | -238.52% | -774.52% | -2,156.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| EPS Diluted | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| Weighted Avg Shares Out | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
| Weighted Avg Shares Out (Dil) | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
-- Third quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $22.5 million -- -- More than 100 international patients on reimbursed IMCIVREE therapy --
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
-- CADTH recommends reimbursement for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS) -- -- Recommendation based on demonstrated clinical benefit in Phase 3 trial --
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Rhythm Pharmaceuticals, Inc. (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today...
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment -- -- Three of 11 pediatric patients with hypothalamic obesity achieved normal weight at one year based on NIH, WHO weight classifications...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases,...
Wall Street Analysts Believe Rhythm Pharmaceuticals, Inc. (RYTM) Could Rally 53.81%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 53.8% in Rhythm Pharmaceuticals, Inc. (RYTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society's Annual Meeting at ObesityWeek ®
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases,...
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases,...
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases,...
Source: https://incomestatements.info
Category: Stock Reports